JB Chemicals & Pharmaceuticals (506943) Presentation at JP Morgan Healthcare Conference summary

Legacy and growth trajectory

• Five decades of brand building, with key milestones including pioneering products in cardiac and GI segments and global expansion since 1976.

• Major acquisitions and transformation post-2020, including KKR buyout, new leadership, and strategic brand acquisitions.

• Achieved INR 30 billion revenue milestone and recognized as fastest-growing cardiology company among top 10 in India.

• Expanded into new therapeutic areas: diabetes, nephrology, pediatrics, respiratory, and virology.

• Launched ESG journey with maiden sustainability report and received industry awards for company and CEO.

Business purpose, values, and impact

• Purpose centers on enriching patients' lives, supporting healthcare providers, and creating sustainable stakeholder value.

• Core values include simplicity, reliability, and agility in adapting to healthcare industry changes.

• Treated 10 million hypertensive patients and 8 million GI patients annually; 1 billion lozenges distributed globally.

• 150 million prescriptions generated in India, with 250,000 HCPs covered.

• Significant reach in IVF, heart failure, and therapy awareness initiatives.

Financial performance and capital efficiency

• FY24 revenue reached INR 34,840 million, with 18% CAGR (FY20-24) and 26% CAGR in operating EBITDA.

• Domestic revenue contributed 54% in FY24; chronic therapies made up 48% of domestic business.

• ROCE improved to 27% in FY24, with strong cash flow conversion and reduced net working capital days.

• Operating EBITDA margin increased to 29% in H1FY25.